Bloodstream Infection Testing

Global Bloodstream Infection Testing Market to Reach US$17.1 Billion by 2030

The global market for Bloodstream Infection Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Conventional Testing, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$12.7 Billion by the end of the analysis period. Growth in the Non-Conventional Testing segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.4% CAGR

The Bloodstream Infection Testing market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Bloodstream Infection Testing Market - Key Trends and Drivers Summarized

Why Is Bloodstream Infection Testing a Cornerstone in Medical Diagnostics?

Bloodstream infection (BSI) testing plays a pivotal role in medical diagnostics, as it is crucial for the early detection and treatment of sepsis, a life-threatening condition caused by an overwhelming immune response to infection. BSIs can result from a variety of pathogens, including bacteria, fungi, and viruses, and their rapid identification is essential to prevent the progression to severe sepsis or septic shock, both of which are associated with high mortality rates. Timely BSI testing allows healthcare providers to administer appropriate antimicrobial therapies, thereby reducing the risk of complications and improving patient outcomes. As a cornerstone of infection control in hospitals, BSI testing is also vital in preventing the spread of infections, particularly in critical care units where patients are most vulnerable.

How Are Technological Innovations Transforming Bloodstream Infection Testing?

The landscape of bloodstream infection testing is being transformed by rapid advancements in technology, which are enhancing the speed, accuracy, and comprehensiveness of diagnostics. Traditional blood culture methods, which can take days to deliver results, are being supplemented or replaced by advanced molecular diagnostic techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing (NGS). These technologies enable the rapid identification of pathogens, often within hours, allowing for earlier and more targeted treatment interventions. Additionally, the advent of point-of-care (POC) testing devices is bringing BSI diagnostics closer to the patient, facilitating quicker decision-making in emergency and remote healthcare settings. The integration of artificial intelligence (AI) and machine learning algorithms into diagnostic platforms is also enhancing the interpretation of complex data, leading to more accurate diagnoses and better patient management.

What Challenges and Regulatory Pressures Are Shaping the Bloodstream Infection Testing Market?

The bloodstream infection testing market is shaped by a complex interplay of challenges and regulatory pressures. One of the primary challenges is the need for highly sensitive and specific tests that can accurately identify a wide range of pathogens, including those that are difficult to culture or detect. This demand has led to significant investment in research and development, driving innovation in diagnostic technologies. At the same time, regulatory bodies such as the FDA and the European Medicines Agency impose stringent standards for the approval of new testing methods, ensuring that only the most effective and safe diagnostics are brought to market. These regulations are critical for maintaining the quality and reliability of BSI testing but also pose barriers to market entry for smaller companies and startups. Additionally, the growing concern over antibiotic resistance is influencing the development of BSI tests that can provide not only pathogen identification but also insights into antibiotic susceptibility, thereby guiding more effective treatment decisions.

What Are the Key Drivers Behind the Growth of the Bloodstream Infection Testing Market?

The growth in the bloodstream infection testing market is driven by several factors, including the rising incidence of hospital-acquired infections (HAIs) and the increasing prevalence of drug-resistant pathogens, which heighten the need for rapid and accurate diagnostics. The global burden of sepsis, particularly in aging populations and immunocompromised patients, is also fueling demand for advanced BSI testing solutions. Furthermore, the shift towards personalized medicine and the need for precise, pathogen-specific treatment regimens are driving the adoption of cutting-edge molecular diagnostics in BSI testing. Technological advancements, such as the development of automated and high-throughput testing platforms, are reducing the time to diagnosis, which is critical in managing BSIs effectively. Additionally, the expansion of healthcare infrastructure in emerging markets and the increasing awareness of sepsis among healthcare providers and the general public are contributing to market growth. As healthcare systems worldwide continue to prioritize infection control and antimicrobial stewardship, the demand for efficient and reliable bloodstream infection testing is expected to rise, driving further innovation and expansion in this critical market segment.

SCOPE OF STUDY:

The report analyzes the Bloodstream Infection Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Conventional Testing, Non-Conventional Testing)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Becton, Dickinson & Company
• bioMerieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.